AI-Driven Advancements in Neuroblastoma Diagnosis and Bone/Bone Marrow Metastasis Prediction
Groundbreaking Study Unveils Key Mechanisms in Neuroblastoma Bone and Bone Marrow Metastasis
EINPresswire.com / -- Neuroblastoma (NB), the most prevalent extracranial solid tumor among children, is characterized by a high rate of metastasis. The pathogenesis of NB with bone or bone marrow metastasis (NB-BBM) and its complex immune microenvironment remain poorly understood, posing challenges for effective risk prediction for BBM and limiting therapeutic strategies.
This research, published in the Genes & Diseases journal by a team from The Children's Hospital of Chongqing Medical University, highlights key genomic and single-cell transcriptomic alterations in NB-BBM, underscoring the significance of predictive pathology for NB-BBM and its role in understanding tumor onset, progression, and heterogeneity.
The researchers used a Swin-Transformer deep learning model to analyze 142 paraffin-embedded hematoxylin-eosin-stained tumor section images to predict NB-BBM occurrence, achieving a classification accuracy exceeding 85%. In parallel, single-cell transcriptomics identified a tumor cell subpopulation (NB3) and two tumor-associated macrophage (TAM) subpopulations (SPP1+ TAMs and IGHM+ TAMs) closely associated with BBM progression. Interestingly, findings reveal that oxidative phosphorylation (OXPHOS) also plays a crucial role in BBM development.
Additionally, this study highlighted transketolase (TKT) as a crucial metabolic molecule linked to BBM. The researchers showed that the TKT gene was strongly associated with the clinical features of NB patients, especially in the BBM group. Functional experiments validated TKT's involvement in malignant behavior, while pathway enrichment analysis showed correlations between high TKT expression and cell cycle activity.
Moreover, expression analysis of immune checkpoint genes CD274, LAG3, and TIGIT revealed their significant upregulation in NB-BBM, suggesting potential targets for antibody-based immunotherapies. Furthermore, immunohistochemical validation demonstrated a pronounced expression of PD-L1 in NB-BBM, indicating its potential as a biomarker.
Although this research provides a predictive model for NB-BBM risk assessment, it has certain limitations, including the need for multicenter validation of the predictive model and prospective studies to confirm clinical utility. Despite these challenges, this study offers a pathodiagnostic prediction for the risk of NB-BBM, enhances other imaging diagnoses, and elucidates the cellular heterogeneity of initial, progressive, and distant metastatic sites in NB.
Reference
Title of the original paper - Integrated multi-omics characterization of neuroblastoma with bone or bone marrow metastasis
Journal: Genes & Diseases
Genes & Diseases is a journal for molecular and translational medicine. The journal primarily focuses on publishing investigations on the molecular bases and experimental therapeutics of human diseases. Publication formats include full length research article, review article, short communication, correspondence, perspectives, commentary, views on news, and research watch.
DOI: https://doi.org/10.1016/j.gendis.2024.101511
Funding Information:
Key Project of the National Key R&D Plan 'Research on Prevention and Control of Major Chronic Non-Communicable Diseases' (China)
Ministry of Science and Technology of the People's Republic of China
National Key R&D Program of China (No. 2018YFC1313000, 2018YFC1313004)
# # # # # #
Genes & Diseases publishes rigorously peer-reviewed and high quality original articles and authoritative reviews that focus on the molecular bases of human diseases. Emphasis is placed on hypothesis-driven, mechanistic studies relevant to pathogenesis and/or experimental therapeutics of human diseases. The journal has worldwide authorship, and a broad scope in basic and translational biomedical research of molecular biology, molecular genetics, and cell biology, including but not limited to cell proliferation and apoptosis, signal transduction, stem cell biology, developmental biology, gene regulation and epigenetics, cancer biology, immunity and infection, neuroscience, disease-specific animal models, gene and cell-based therapies, and regenerative medicine.
# # # # # #
CN: 50-1221/R
Genes & Diseases
+86 23 6571 4691
X
LinkedIn
Instagram
YouTube
Other
Legal Disclaimer:
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 days ago
- Yahoo
My best friend died at 11 after telling me to live my life for him
Ryan Quinn remembers the first time he met Aaron Murphy, the boy who would become his best friend. He was three and it was his first day at nursery. "After my mum dropped me off, I got very upset. It was the first time that I'd been on my own without her," he said. "As I turned around to go and find her, Aaron was standing behind me. We became inseparable instantly. "We were the closest of friends. We had so much in common. We had a love for Minecraft and for Star Wars." Just months into the friendship between the two boys from Dunfermline, Aaron Murphy was diagnosed with neuroblastoma - a rare form of childhood cancer which develops in nerve tissue and usually affects children under five. After various treatments, Aaron's cancer entered remission. But when he was 10, his cancer returned. He went through further treatment, but there was nothing that could save him. He died three weeks shy of his 12th birthday. Ryan was supposed to visit Aaron in hospital that evening but was picked up from school early. "I was so excited," he said. But the atmosphere in the car on the way home was silent. "When home, my mum sat down next to me and put her arms around me. 'Aaron's gone, Ryan,' she said." Losing a close friend at the age of 11 brought unimaginable grief to Ryan. He was angry at the world and at the disease that took his friend. "I became very reclusive and very depressed," said Ryan. "About three months after Aaron passed away, I started high school, which was hard because it was a massive change. "Suddenly I started this new school where I didn't really know anyone and my best friend wasn't there." On what would have been Aaron's 18th birthday, Ryan has shared what it was like to lose his childhood friend while they were both children themselves. Now 17, Ryan wants to turn his grief into a vehicle for change. "I thought I could put the anger and passion I felt into something - which was campaigning for children's cancer and raising awareness," he told BBC Scotland News. Aaron's last words to his friend were "Live your life for me, Ryan" and that is what he is trying to do. He says he is determined to honour his request. Ryan has undertaken fundraising and lobbying. Last year he did a sky-dive in memory of Aaron to raise money for a charity called the Team Jak Foundation which provides support for families and friends of people affected by cancer. It helped Ryan to deal with his grief and he said he wanted to pay them back. Earlier this year he spoke at the Scottish Labour Party conference. After that he managed to secure a meeting with Scotland's Health Minister Neil Gray who invited him to the Scottish Parliament to discuss the issues that Ryan is highlighting. Mr Gray told Ryan he was committed to improving outcomes for children and young people with cancer. Thoughts turned to Aaron during the meeting. "I thought, 'What would Aaron think of what I'm doing?' "There was one empty chair at the table. "I am confident that Aaron was sat in it, and I hope I did him proud." June is a hard month for Ryan. As he reaches adulthood, he has lots of questions about what happened to his best friend. He said " Recently I bought my first car after passing my driving test and the first thought I had when I put the key into the ignition was 'Why do I get to do this and Aaron doesn't?' And I'm constantly reminded of that as we approach Aaron's 18th birthday." Six years on from Aaron's death, Ryan says he misses his friend more than ever. "I loved Aaron with my whole heart and I always will," he said. "Aaron's death inspired me to be a campaigner so that he and the other children and young people who die from cancer each year are never forgotten. "I want to make sure that Aaron's story gets to the right places and on the right people's desks and I hope that meaningful change will be made." More stories from Edinburgh, Fife & East More stories from Scotland 'Radiographer started crying during my cancer scan'
2 days ago
What to know about COVID variant NB.1.8.1 causing 'razor blade throat'
A newer COVID-19 variant may be causing a severe sore throat in some people who contract the infection. The variant, known as NB.1.8.1, has been nicknamed by some as "razor blade throat" due to the painful symptom. Data from the open global genome sequencing database GISAID shows the new variant has been detected in several states, including New York, Illinois, Texas and California. Public health experts told ABC News there is no cause for serious concern yet because the virus does not appear to be more severe than previous variants and there are steps that can be taken to protect yourself. What is NB 1.8.1? NB.1.8.1 derives from the recombinant variant XVD.1.5.1, which is a descendant of the omicron variant. The first sample of NB.1.8.1 was collected on Jan. 22, according to the World Health Organization (WHO). It was first detected in China and other parts of Asia before spreading to Europe. It was designated as a "variant under monitoring" by the WHO, meaning it may require prioritized attention and monitoring but is not as serious as a "variant of interest" or a "variant of concern." As of the week ending June 7, NB.1.8.1 is the second most dominant variant in the U.S., accounting for an estimated 37% of cases, according to the Centers for Disease Control and Prevention (CDC). The virus appears to be more transmissible because there appear to be changes to the spike protein, which is what the virus uses to attach to and infect cells, said Dr. Peter Chin-Hong, a professor of medicine and infectious disease specialist at the University of California, San Francisco. It also seems to attach more easily to ACE2 receptors, which are proteins found on the surface of cells and how the virus that causes COVID enters cells, he told ABC News. NB.1.8.1 doesn't yet appear to be causing increases in cases or in hospitalizations with rates remaining "stable" so far, according to Chin-Hong. The variant has also been called "Nimbus," which appears to have been coined on X by T. Ryan Gregory, a Canadian professor of evolutionary biology. "Nimbus is a catchy, quick name, and it also includes an 'N' and a 'B' from the lineage, which is NB.1.8.1. So it's easier for people to be able to say these monikers for COVID, rather than remember the actual lineage," said Dr. Alok Potel, a pediatrician at Stanford Children's Health and an ABC News contributor. "But I think it's important also because it keeps people paying attention to new COVID variants that can be different in terms of infectivity and in terms of spread," he added. What are the symptoms? Experts said they are not sure if the painful sore throat is just a symptom that people are talking about or a distinctive symptom of this variant. It's also unclear if the "razor blade throat" is more common in those who are more up to date on vaccination compared to those who are not up to date. "I think it's certainly amongst the spectrum of symptoms that you can get, and we know that sore throat is reported by about 70% of patients now with COVID, so it's not unusual, and like with everything in medicine, there's always a spectrum," Chin-Hong said. There is currently no evidence that NB.1.8.1. causes more severe disease or is more likely to cause hospitalization, according to Dr. William Schaffner, a professor of preventive medicine at Vanderbilt University Medical Center in Nashville, "But of course, there are people in high-risk groups that are still at risk of being hospitalized should they become infected," he told ABC News. There are no other symptoms outlined that are specific to NB.1.8.1 by the CDC. Symptoms listed by the health agency still include sore throat, cough, fever, chills, shortness of breath, difficulty breathing, congestion, runny nose, loss of taste or smell, fatigue, muscle aches, body aches, headache, nausea, vomiting or diarrhea. How to protect yourself The experts recommend that high-risk Americans receive a vaccine twice a year as recommended by the CDC. The CDC also currently recommends most adults aged 18 and older receive an updated 2024-2025 vaccine and that parents of children between ages 6 months to 17 years discuss the benefits of vaccination with a health care provider. COVID-19 also tends to spike in the late summer and early fall, so people should consider opening windows to increase ventilation, wearing a mask in certain situations and avoiding crowded areas, Schaffner said. "Time to stream a movie, as I like to say, rather than going to the movies," he added. Patel said it's important to practice good hygiene such as proper hand-washing and covering your mouth when coughing or sneezing. He also recommended that people test if they are symptomatic and said over-the-counter rapid at-home tests work. "Getting infected with COVID and other infectious diseases is not necessarily life or death, but it can still be very debilitating." Patel said. "It can cause people to miss work, to spread the virus, to get people who are higher risk sick and there's still an untold amount of people who have long COVID." He added, "So, we don't want to look at COVID as just another common cold, because there's still so much we're learning about it, and there's still so many possibilities with this virus continuing to mutate, if we let it."
CBS News
2 days ago
- CBS News
Alex's Lemonade Stand Foundation funding research for newborn screening for genetic predisposition to cancer
Alex's Lemonade Stand Foundation aims to cure the incurable, and its Crazy 8 Initiative supports research into the most challenging problems in childhood cancers. This year, two major projects could be game changers and even lifesavers. You probably remember Cole Fitzgerald's smile, a friend of ours at CBS Philadelphia and a cancer hero of the Alex's Lemonade Stand Foundation who passed away in 2023. Fitzgerald had neuroblastoma as a child and was cancer-free for 15 years when he was diagnosed with metastatic pancreatoblastoma. His parents say they learned during his final fight that he had a genetic predisposition to cancer. "That's when they discovered that he had [Li-Fraumeni syndrome], which meant that one of us potentially passed it on to him," Karen Fitzgerald said. "It is a genetic predisposition where a particular gene called the TP53, which is in normal DNA, is a tumor suppressor. And in people that have LFS that tumor suppressor does not function." "Probably around 10% of children develop cancer because they have a genetic risk for cancer," said Dr. Lisa Diller, a pediatric oncologist at the Dana-Farber Cancer Institute and Boston Children's Hospital. "Well, there are some genes that we can find in children that tell us that a child is at risk for cancer," Diller said, "and then we can do screening and find it early. And maybe use very minimal therapy to cure that child so they don't need chemotherapy, they don't need radiation, or we increase their chance of being cured." The testing would be part of routine heel stick blood tests on newborns. "We pick up children at risk for cystic fibrosis and for a variety of rare genetic disorders," Dr. Sharon Plon, the chief of the cancer genetics clinic at Texas Children's Hospital, said. "And we're able to treat them or do surveillance. But we've never done that for cancer." If a genetic risk of cancer is found, children would be screened regularly through childhood and into adulthood. "Cole would have had a different level of surveillance after his first incident rate of cancer," Karen Fitzgerald said. "When you're getting yearly MRIs of the brain and the body and all the additional blood testing as well." Although Karen Fitzgerald learned that she and other family members also have the genetic predisposition, she and her husband considered it a last gift from Cole. Another group of researchers is working on vaccines. The Crazy 8 Initiative allows researchers to take risks — risks that are necessary to find treatments, cures, and hopefully, vaccinations. "I don't think this would be possible to get funded through any other traditional mechanism that I've heard of," Dr. David Malkin with the Hospital for Sick Children and the University of Toronto said. "The Alex's Crazy 8 grant is going to get us to the point that this is actually can be something that can be something that can be in clinical trials in children." "It's too late for Cole, but to see these grants and what they're doing and the possibility to save others that have the same predisposition," Bill Fitzgerald said. "He would be thrilled, delighted," Karen Fitzgerald. "He would say, let's go."
